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Abstract
Objectives. To investigate whether the auto-inflammatory nature and the pathergic reaction in Behçet’s disease
(BD) are driven by a disturbed toll-like receptor (TLR) response.
Methods. We compared both TLR expression by flow-cytometry and TLR response by stimulation assay in 18 BD
patients (both pathergy positive and pathergy negative) with 15 healthy controls.
Results. Expression of TLR1 and 2 was significantly elevated in B-lymphocytes of BD patients compared with
healthy controls. TLR1, 2 and 4 were significantly more highly expressed in both CD4þ and CD8þ T-lymphocytes
of BD patients. Granulocytes of BD patients displayed significantly higher expression of TLR1, 2, 4 and 6. TLR2, 4
and 5 expression was significantly increased on classical monocytes of BD patients. Intermediate monocytes of BD
patients showed an increase in expression of TLR2. Furthermore, TLR2 and 5 were significantly more highly
expressed in non-classical monocytes of BD patients. In pathergy positive patients, TLR5 was even more highly
expressed compared with pathergy negative patients on B- and T-lymphocytes and granulocytes. Furthermore,
TLR2 and 5 showed an elevated TNF-a response to stimulation with their cognate ligands.
Conclusion. Immune cells of BD patients overexpress TLR1, 2, 4, 5 and 6. Furthermore, after stimulation of TLR2 and
5, BD patients demonstrate a more potent TNF-a response. Although this is a small cohort, in the pathergy positive
patients, TLR5 expression is even further augmented, suggesting that a microbial (flagellin) or damage (HMGB1) associ-
ated signal may trigger the exaggerated immune response that is characteristic for the pathergy phenomenon in BD. In
conclusion, these results point to an exaggerated TLR response in the auto-inflammatory nature of BD.
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Introduction
Behçet’s disease (BD) is an auto-inflammatory vasculitis
of unknown origin, affecting predominantly the orogeni-
tal mucosa, skin and eyes [1]. The clinical symptoms of
BD relate to a disturbed T cell response; however,
increasing evidence suggests an auto-inflammatory na-
ture rather than an auto-immune nature [2]. Auto-
inflammatory disorders are characterized by excessive
innate immune responses, causing a hyper-inflammatory
state [3].
In BD this hyper-inflammatory state is reflected by
elevated serum cytokine levels, for instance TNF-a, IL-
1b and IL-18 [4, 5]. Additional evidence of innate im-
mune activation in BD is increased neutrophil activity [6]
and elevated numbers of gamma delta T-lymphocytes,
both in circulation and at inflammatory sites [7].
Furthermore, it has been proposed that HLA-B51 mis-
folding may cause endoplasmic reticulum stress thereby
inducing an inflammatory response, comparable to HLA-
B27 in spondylarthropathy [2, 8]. The BD-specific
pathergy test [9] reveals an exaggerated inflammatory
cutaneous response to sterile-needle-induced tissue
damage. This suggests a role for innate pattern recogni-
tion receptors, including toll-like receptors (TLRs) [10].
TLRs are pathogen recognition receptors of which
certain family members are expressed at the cell mem-
brane surface (TLR 1, 2, 4, 5, 6 and 10), while others are
typically expressed in the endosomal compartment
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within the cytosol (TLR 3, 7, 8 and 9) [11]. TLRs are pre-
sent in virtually all immune cells and specialized in the
recognition of conserved motifs present in pathogens
[the so-called pathogen-associated molecular patterns
(PAMPs)], and of endogenous molecules released upon
tissue injury [the so-called damage-associated molecular
patterns (DAMPs)]. Upon PAMP or DAMP binding, TLRs
activate the transcription factor nuclear factor-jB (NF-
jB) in a MyD88-dependent manner. Exceptions are
TLR3, which uses TIR-domain-containing adaptor-induc-
ing interferon-b (TRIF) to activate NF-jB, while TLR4
can signal through both pathways [12]. NF-jB activation
stimulates production of pro-inflammatory molecules,
including TNF-a, which is a key cytokine in the mechan-
istic pathway of BD [2, 13].
Data on TLR expression and activation in BD are in-
consistent. Liu et al. demonstrated elevated TLR 2, 3, 4
and 8 expression in peripheral blood mononuclear cells
(PBMCs) of BD patients compared with healthy controls
[14]. Stimulation with specific TLR2 and 4 ligands results
in elevated IL-1b and IL-23 production by monocytes of
these patients as well as increased IL-17 production in
T-lymphocytes and monocytes, compared with healthy
controls. Seoudi et al. showed increased TLR2 and 4
mRNA expression in oral tissue from BD patients, but
diminished activation of PBMCs upon stimulation with
specific TLR1/2 and TLR4 ligands, compared with
PBMCs from healthy controls [15]. Yavuz et al.
described decreased TLR6 expression in granulocytes
from BD patients, while expression of TLR1, 2 and 4 in
granulocytes and monocytes was comparable to healthy
controls [16]. Besides these discrepant data on TLR ex-
pression, no other data on TLR expression in relation to
the pathergy test response in BD is available.
The goal of this work was therefore to thoroughly study
the relationship between TLR expression/activity and to
explore the relationship between TLRs and the pathergy
test response in patients with BD. Expression levels of TLR
1, 2, 4, 5 and 6 by peripheral blood cells from pathergy test
positive and pathergy test negative BD patients were
studied. In addition, TNF-a production response by
PBMCs upon stimulation with specific TLR ligands was
examined. Our study reveals increased expression of
TLR1 and 2 on B cells, T cells and granulocytes, increased
expression of TLR2 on different monocyte subsets (clas-
sical, pro-inflammatory/intermediate and non-classical
monocytes), increased expression of TLR4 on B cells, T
cells, granulocytes and classical monocytes and increased
expression of TLR5 on granulocytes, classical and non-
classical monocytes. In addition, elevated TNF-a secretion
upon stimulation with TLR2 and TLR5 ligands is shown.
Moreover, pathergy test positive BD patients are charac-
terized by higher expression of TLR5 on B cells, T cells
and granulocytes compared with pathergy test negative
BD patients. The data indicate that altered TLR expression
and activity could contribute to the excessive innate im-
mune activation observed in BD and may partly explain the
pathergy phenomenon observed in some BD patients.
Methods
Patients
Diagnostic work-up and detailed examination of blood
from 18 patients with BD (diagnosed according to the
International Study Group of BD Criteria [17]) and 15
healthy controls (age, gender and ethnicity matched)
were performed following written informed consent
according to the Declaration of Helsinki. The study was
approved by the Medical Ethical Committee of the
Erasmus MC (MEC-2011-172). Disease activity was
measured using the BD Current Activity Form (BDCAF)
[18]. A pathergy test was conducted in the diagnostic
process according to International Study Group of BD
Criteria [17]; both pathergy positive and pathergy nega-
tive patients were included.
Flowcytometric measurement of TLR expression
Heparinized whole-blood samples (200ml) from BD
patients and controls were lysed with ammonium chlor-
ide and washed with PBS containing 0.5% bovine
serum albumin and incubated for 10 min with the follow-
ing antibodies: CD45-PerCP, CD33-allophycocyanine
(APC), CD16-PE-Cy7, CD8-APC-Cy7, CD14-APC-Cy7,
CD20-APC-Cy7 (all from BD Biosciences, San Jose, CA,
USA), CD19-PE-Cy7 (from Beckman Coulter, Fullerton,
CA, USA), CD1c-FITC, TLR1-PE, TLR2-PE, TLR4-PE (all
from eBioscience, San Diego, CA, USA), TLR5-FITC
(from Abcam, Cambridge, UK) and TLR6-PE (from
Biolegend, San Diego, CA, USA). Samples were meas-
ured on a flow cytometer (FACSCanto II machine; BD
Biosciences) and analysis was performed with Infinicyt
1.7 flow cytometry software (Cytognos S.L., Salamanca,
Spain).
Lymphocytes were defined as CD45 positive and
low on sideward scatter. Within lymphocytes the follow-
ing subsets were determined: B-lymphocytes
(CD19þCD20þCD3), CD4 T-lymphocytes (CD3þCD4þ)
and CD8 T-lymphocytes (CD3þCD8þ). Monocytes were
Rheumatology key messages
. Altered toll-like receptor (TLR) expression and activity could contribute to the inordinate innate immune activa-
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defined as CD45þ with intermediate sideward scatter
and subtyped based on CD14 and CD16 expression:
classical (CD14þþCD16), intermediate (CD14þþCD16þ)
and non-classical (CD14dimCD16þþ) monocytes.
Granulocytes were determined on the basis of high side-
ward scatter and CD45dim expression. TLR expression
level was measured using mean fluorescence intensity
(MFI). The flow cytometer was calibrated according to a
standardized instrument setting described in detail in
the EuroFlow protocols [19]. The instrument setting used
ensures that major leucocyte populations are gated in
the window of analysis at a comparable location at each
time and allows for MFI comparisons between samples.
Ex vivo stimulation of whole blood by TLR ligands
To determine the response to extracellular TLR activa-
tion, whole blood of therapy naı̈ve BD patients (n¼ 6)
and healthy controls (n¼3, ethnicity, age and gender
matched) was stimulated with TLR-specific ligands, as
described before [20]. Briefly, 50 ml of whole blood was
stimulated with one of the following ligands for 6 h at
37C, 5% CO2: the TLR1 ligand Pam3CSK4 (100 ng/ml),
the TLR2 ligand Staphylococcus aureus derived lipotei-
choic acid (1 mg/ml), the TLR4 ligand lipopolysaccharide
(LPS; 1 ng/ml Escherichia coli ultrapure), the TLR5 ligand
flagellin (1 mg/ml, purified flagellin from Salmonella typhi-
murium) or the TLR6 ligand fibroblast stimulating lipo-
peptide 1 (FSL-1; 1mg/ml). All TLR ligands were
obtained from InvivoGen (San Diego, CA, USA).
Hereafter, culture supernatant was collected and stored
at 80C until further analysis. TNF-a in the superna-
tants was determined by enzyme-linked immunosorbent
assay (Biosource Europe SA, Nivelles, Belgium, human
TNF-a CytoSets).
Statistical analysis
Statistical analysis was performed using the Mann–
Whitney test (SPSS Statistics version 21.0, IBM Corp.,




In total 12 patients [mean age 40 years (range 26–
59 years), male: female 1:1.4] and 12 healthy controls
[mean age 45 years (range 21–62 years), male: female
1:1] were included. Patients were at the time of study in-
clusion treated with colchicine (n¼5), adalimumab
(n¼4) or colchicine and adalimumab (n¼1), or therapy
naı̈ve (n¼ 2). In addition to this, to test the peripheral
blood TNF-a response after ex vivo stimulation with spe-
cific TLR ligands, we included six therapy naı̈ve patients
[mean age 32 years (range 23–43) male: female 1:5] and
compared these with 3 healthy controls [mean age
28 years (range 26–30) male: female 1:2] (Table 1).
TLR expression in BD patients
B-lymphocytes of BD patients expressed TLR1 and 2
significantly more than healthy controls (both P<0.05),
and there was a trend towards increased expression of
TLR4, 5 and 6 (Fig. 1A).
In both CD4þ and CD8þ T-lymphocytes of BD
patients, TLR1 displayed the most significant increased
expression compared with healthy controls (P< 0.01 in
both CD4þ and CD8þ T-lymphocytes). Also TLR2 and 4
showed a significantly increased expression on CD4þ
and CD8þ T-lymphocytes of BD patients (both P<0.05).
A trend towards increased expression of TLR5 and 6
was seen in CD4þ and CD8þ T-lymphocytes (Fig. 1B
and C).
TLR1, 2, 4 and 6 were significantly more highly
expressed (P< 0.01, P< 0.001, P<0.01, P<0.05, re-
spectively) on granulocytes from BD patients. In add-
ition, granulocytes from BD patients displayed higher
TABLE 1 Patient characteristics
Characteristic Patients (n 5 12) Therapy naı̈ve
patients (n 5 6)
Healthy
controls (n 5 15)
Females, % 58 83 67
Age, mean (range), years 40 (26–59) 32 (23–43) 42 (21–62)
Clinical manifestations, %
Oral ulceration 100 100
Genital ulceration 92 67
Uveitis 42 17
Skin lesions 92 83
Pathergy 67 67
HLA-B51 42 67
First-line medication 42 0
Second-line medication 42 0
Disease activity, median BDCAF 2 3
First line medication is colchicine (n ¼ 5). Second-line medication is adalimumab (n ¼ 5). BDCAF: Behçet’s Disease
Current Activity Form.
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TLR5 expression than controls, although this was not
statistically significant (P¼ 0.08) (Fig. 1D).
Classical monocytes of BD patients expressed signifi-
cantly higher levels of TLR2 (P< 0.05), TLR4 (P<0.05)
and TLR5 (P< 0.05) compared with healthy controls.
TLR2 was also expressed at higher levels by the inter-
mediate (P<0.05) and non-classical (P< 0.05) mono-
cytes of BD patients. In addition to this, non-classical
monocytes displayed a significantly higher TLR5 expres-
sion (P< 0.05). The distribution of monocytes in BD
patients was comparable to healthy controls. Data are
summarized in Table 2. Table 3 shows a summary of
TLR expression in the examined leucocyte subsets.
TLR expression in pathergy positive patients
Pathergy positive BD patients displayed significantly
higher expression of TLR5 in B-lymphocytes and CD4þ
and CD8þ T-lymphocytes compared with pathergy
negative BD patients (P< 0.05) (Fig. 2). In addition to
this, a trend towards higher TLR6 expression by B-lym-
phocytes, CD4þ and CD8þ T-lymphocytes of pathergy
positive patients was observed.
TLR5 was also expressed at significantly (P<0.05)
higher levels by granulocytes of pathergy positive BD
patients than those of pathergy negative patients
(Fig. 2). Moreover, TLR1 expression by granulocytes
from pathergy positive BD was significantly (P<0.01)
lower than that of pathergy negative BD patients (Fig. 2).
Classical monocytes of pathergy positive BD patients
displayed a significantly (P< 0.05) higher expression of
TLR6 compared with pathergy negative BD patients
(Table 2). Moreover, classical, intermediate and non-
classical monocytes of pathergy positive BD patients
displayed a trend towards increased expression of TLR5
(Table 2).
HLAB51 positivity or medication did not correlate with
TLR expression by any of the leucocyte subsets ana-
lysed (data not shown). Table 3 shows a summary of
TLR expression on the examined leucocyte subsets.
TLR response to stimulation in whole blood samples
Peripheral blood cells from BD patients produced signifi-
cantly more TNF-a when stimulated with the TLR2 lig-
and lipoteichoic acid or the TLR5 ligand flagellin
compared with healthy controls (Fig. 3, both P<0.05).
In contrast, upon stimulation with FSL-1, which activates
the TLR2/6 complex, peripheral blood cells from BD
patients tended to produce less TNF-a than healthy
controls, although this difference was not statistically
significant. Stimulation of peripheral blood cells with the
TLR4 ligand LPS or the TLR1/2 ligand PAM3CSK4
revealed no differences in TNF-a production between
patients and healthy controls.
Discussion
This study demonstrates increased expression of TLR1,
2, 4, 5 and 6 by lymphoid and myeloid cells of patients
with BD compared with healthy controls. Moreover,
Fig. 1 TLR expression in BD patients and healthy controls
TLR expression in B-lymphocytes (A), CD4þ (B) and CD8þ (C) T-lymphocytes and granulocytes (D). Illustrated in black
are BD patients; white represents healthy controls. Expression is shown as mean fluorescence intensity. The expres-
sion of the measured TLRs of a representative patient is shown in the curve on the right. Differences between con-
trols and patient groups were statistically analysed using the Mann–Whitney test: *P< 0.05; **P< 0.01; ***P<0.001.
BD: Behçet’s disease; HC: healthy control; MFI: mean fluorescence intensity; TLR: toll-like receptor.
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pathergy test positive BD patients display even higher
TLR5 expression on B-lymphocytes, CD4þ T-lympho-
cytes, CD8þ T-lymphocytes and granulocytes than do
BD patients with a negative pathergy test. Furthermore,
PBMCs from BD patients produce more TNF-a upon ac-
tivation of TLR2 or 5 than PBMCs from healthy controls.
We have demonstrated that BD patients with a posi-
tive pathergy test have a significantly higher TLR5 ex-
pression level on B-lymphocytes, CD4þ T-lymphocytes,
CD8þ T-lymphocytes and granulocytes compared with
pathergy negative BD patients. TLR5 acts by recognition
of bacterial flagellin. Higher expressed levels have not
been demonstrated in BD so far. Overexpression of
TLR5 on monocytes has been associated with inflam-
matory responses in elderly. In addition to this, overex-
pression of TLR5 has been found on monocytes and
peripheral blood lymphocytes in SLE and acute graft-vs-
host disease [21–23]. In another auto-inflammatory dis-
ease that is clinically related to BD, Crohn’s disease,
TLR5 activation is considered to contribute to the




compared with pathergy negative patients
TLR1 TLR2 TLR4 TLR5 TLR6 TLR1 TLR2 TLR4 TLR5 TLR6
B cells þþ þþ ns ns ns ns ns ns þþ ns
CD4þ T cells þþ þþ þþ ns ns ns ns ns þþ ns
CD8þ T cells þþ þþ þþ ns ns ns ns ns þþ ns
Granulocytes þþ þþ þþ ns þþ  ns ns þþ ns
Classical monocytes ns þþ þþ þþ ns ns ns ns ns ns
Intermediate monocytes ns þþ ns ns ns ns ns ns ns ns
Non-classical monocytes ns þþ ns þþ ns ns ns ns ns þþ
Significant increase in TLR expression is displayed as þþ. Significant decrease in TLR expression is depicted as . ns:
no significant differences; TLR: toll-like receptor.








Cell number, median (range), 109/l
Monocytes 0.79 (0.12–2.17) 0.85 (0.32–1.71) 0.56
Classical monocytes 0.44 (0.07–0.98) 0.58 (0.02–1.44) 0.52
Intermediate monocytes 0.26 (0.01–1.25) 0.14 (0.05–0.23) 0.52
Non-classical monocytes 0.08 (0.01–0.14) 0.08 (0.02–0.14) 0.85
TLR expression in MFI, median (range), 106
Classical monocytes
TLR1 5.8 (0.5–7.4) 3.5 (0.2–9.0) 0.17 5.8 (0.5–6.3) 6.0 (4.0–7.4) 0.32
TLR2 5.6 (0.3–9.7) 2.6 (0.2–7.7) 0.02 5.2 (0.3–9.7) 6.2 (4.3–7.3) 0.53
TLR4 7.4 (0.7–10.5) 4.2 (0.4–11.0) 0.03 7.4 (0.7–10.5) 7.3 (6.2–8.4) 0.93
TLR5 3.1 (0.1–6.2) 0.4 (0.1–4.4) 0.03 4.4 (0.1–6.2) 1.5 (0.2–3.1) 0.16
TLR6 5.6 (0.5–10.1) 3.4 (0.7–9.2) 0.31 5.6 (1.4–10.1) 3.5 (0.5–7.4) 0.41
Intermediate monocytes
TLR1 7.3 (0.4–18.0) 4.4 (0.0–15.1) 0.08 7.2 (0.4–18.0) 7.9 (5.8–9.3) 0.93
TLR2 7.1 (0.4–14.5) 3.2 (0.3–12.5) 0.03 8.2 (0.4–14.5) 6.7 (5.9–8.8) 0.68
TLR4 8.9 (1.0–13.5) 4.6 (0.6–17.1) 0.21 9.9 (1.0–13.5) 9.2 (6.7–10.0) 0.57
TLR5 5.7 (0.1–8.2) 3.7 (0.0–8.3) 0.05 6.7 (0.2–10.1) 1.4 (0.1–5.7) 0.07
TLR6 7.6 (0.5–13.2) 4.0 (0.1–14.5) 0.28 10.3 (0.6–13.2) 3.9 (0.5–8.7) 0.07
Non-classical monocytes
TLR1 5.1 (0.3–9.1) 3.9 (0.0–9.4) 0.17 5.1 (0.3–9.1) 5.1 (4.4–5.8) 0.93
TLR2 4.8 (0.3–7.6) 3.0 (0.2–7.2) 0.01 5.3 (0.3–7.6) 4.5 (3.8–6.6) 0.79
TLR4 5.6 (0.7–8.5) 4.8 (0.6–10.7) 0.31 5.9 (0.7–8.5) 5.5 (5.2–5.6) 0.41
TLR5 2.4 (0.2–6.3) 0.3 (0.1–4.2) 0.04 4.0 (0.2–6.3) 1.2 (0.2–2.4) 0.11
TLR6 4.7 (0.4–8.3) 3.5 (0.1–9.3) 0.23 6.2 (1.9–8.3) 2.8 (0.4–4.6) 0.02
Cell numbers are depicted as 109/l, as median (range). P-values <0.05 in bold indicate statistical significance. TLR
expression is displayed as the median MFI. MFI: mean fluorescence intensity; TLR: toll-like receptor.
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inflammatory state since antibodies against flagellin are
found in 50% of Crohn’s disease patients. Interestingly,
in a Crohn’s disease mouse model, worsening of colitis
occurs after rectal infusion of flagellin [24, 25]. The ele-
vated response to TLR5 stimulation that we show in our
current study supports the hypothesis that a similar
mechanism might be associated with the immuno-
pathogenesis of BD. Inflammatory infiltrates are domi-
nated by T-lymphocytes, neutrophils and monocytes/
macrophages in BD characteristic pathergic lesions [26–
28]. In these cell types higher levels of TLR5 are
expressed in the pathergy positive patients. Despite the
Fig. 3 TNF-a response to stimulation with TLR agonists in whole blood
TNF-a response to stimulation with TLR ligands. Black scatter dots represents BD patients; white scatter dots illus-
trates TNF-a response in healthy controls. Differences between controls and patient groups were statistically analysed
by using the Mann–Whitney test. BD: Behçet’s disease; FSL-1: fibroblast stimulating lipopeptide 1; HC: healthy con-
trol; hi ¼ high concentration, 10000 ng/ml; lo ¼ low concentration, 1000 ng/ml; LPS: lipopolysaccharide; ns: not sig-
nificant; TLR: toll-like receptor.
Fig. 2 TLR expression in pathergy positive and pathergy negative patients
Differences in TLR expression in B-lymphocytes (A), CD4þ (B) and CD8þ (C) T-lymphocytes and granulocytes (D)
between pathergy positive and pathergy negative patients. Illustrated in black are pathergy positive patients; white
represents pathergy negative patients. Expression is shown in mean fluorescence intensity. The expression of the
measured TLRs of a representative patient is shown in the curve on the right. Differences between patient groups
were statistically analysed by using the Mann–Whitney test: *P<0.05; **P< 0.01. MFI: mean fluorescence intensity;
TLR: toll-like receptor.
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difference in TLR5 expression, we have not observed
any difference in TNF-a production between peripheral
blood cells from pathergy positive BD and pathergy
negative BD patients upon TLR5 stimulation, yet this
might be related to the small number of patients tested
(n¼4 pathergy positive and n¼2 pathergy negative).
Nevertheless, considering the clear differences in TLR5
expression between pathergy positive and pathergy
negative BD patients, we hypothesize that strongly
enhanced TLR5 expression in these cells reflects the
local inflammatory response to danger molecules in BD
patients.
Recently, high mobility group box 1 (HMGB1) was
identified as a TLR5 agonist [29]. HMGB1 is a non-
histone nuclear protein that is known as a DAMP able to
activate the innate immune system via TLR2, 4 and 5. In
pathergy positive BD patients, HMGB1 released from
necrotic cells could act as danger molecule stimulating
the local inflammatory response via the upregulated
TLR5 expression. This hypothesis is further strength-
ened by the elevated HMGB1 levels in serum of BD
patients as found by de Souza et al. [30]. Because of
the known flagellin–TLR5 interaction, it is also possible
that bacterial components contribute to the pathergy re-
action. This is supported by the observed decline of
pathergy positivity after cleaning the skin prior to testing
with 100% chlorhexidine [31]. It can thus be hypothe-
sized that the exaggerated inflammatory cutaneous re-
sponse as seen in a positive pathergy test can be
triggered via the upregulated TLR5 in leukocytes, by
skin-derived flagellin and/or HMGB1 released from nec-
rotic cells.
Increased expression of TLR 1, 2, 4 and 6 in BD
patients has been shown previously, on several different
cell types, including blood cells as well as oral epithelial
cells [14–16, 32], and is further corroborated by our cur-
rent study. Increased TLR expression on immune cells is
not specific to BD, as this has been reported in other in-
flammatory diseases as well, including spondylarthrop-
athy and IBDs [33, 34]. In IBD, TLR2 is more highly
expressed in peripheral blood monocytes; in addition to
this, an increased TNF-a response after stimulation of
TLR2 is found in PBMCs from IBD patients compared
with healthy controls [35]. TLR2 and 4 are also upregu-
lated in PBMCs of patients with spondylarthropathy,
which can be reversed by the TNF-a neutralizing drug
infliximab [36]. One could speculate about the cause of
the increased TLR expression on immune cells from BD
patients, but because of the inflammatory nature of BD,
inflammation-driven enhancement is likely to be
involved. Inflammation modulates TLR expression via
cytokines such as TNF-a, as shown in spondylarthrop-
athy [36]. Also, in intestinal macrophages in IBD there is
an inflammation-induced enhancement of TLR2 and 4
expression [37]. Also, type I IFNs are known to regulate
TLR expression [38]. Recently, in BD a gene array strat-
egy identified upregulated genes participating in type I
interferon and Janus kinase–signal transducer and acti-
vator of transcription signalling pathways [39]. In vitro,
exogenously administered IFN-a or c downregulated
TLR5 gene expression [40]. IFN-a treatment was shown
to be effective in decreasing disease activity in BD [41],
which could be explained by the downregulating effect
of IFN-a on TLR5 expression. These data raise the
question of whether a defect in the IFN-a pathway is
contributive to the pathergy reaction; this should be
investigated in further research.
Limitations to our study could be the use of immuno-
suppressive medication (colchicine, adalimumab). The
effect of colchicine on TLR expression is unknown, but
adalimumab may downregulate TLR expression [36, 42].
In theory, this may lead to underestimation of the actual
overexpression of TLRs in BD. However, we believe that
the impact of such an effect on our findings is limited
since TLR expression was comparable between our
patients when stratified for medication, as is depicted in
Supplementary Fig. 1, available at Rheumatology online.
In addition to this, our stimulation assay was used to
gain insight into the function of the different TLRs, by
measuring response to stimulation. Unfortunately, the
stimulation data lack information regarding which subset
is responsible for the TNF-a production. To gain more
insight into this, co-staining for TNF-a and TLR levels in
the different subsets could be useful.
In conclusion, increased expression of several TLRs in
BD patients suggests a prominent innate driven inflam-
matory response in this disease. Especially TLR2 and
TLR5 might implicate the severity of this response. Also,
the relation with TLR5 and the pathergy test opens inter-
esting new possibilities for future mechanistic studies,
which might unravel the attributional factors that can be
of interest for specific targeted therapy and diagnostic
work-up.
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TLR2 and 4 in Behçet’s disease pathogenesis. Innate
Immun 2014;20:412–22.
16 Yavuz S, Elbir Y, Tulunay A, Eksioglu-Demiralp E,
Direskeneli H. Differential expression of toll-like receptor
6 on granulocytes and monocytes implicates the role of
microorganisms in Behcet’s disease etiopathogenesis.
Rheumatol Int 2008;28:401–6.
17 International Study Group for Behçet’s Disease. Criteria
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pathergy reaction in Behçet’s disease. Br J Dermatol
2010;132:901–7.
27 Jorizzo JL, Solomon AR, Cavallo T. Behçet’s syndrome.
Immunopathologic and histopathologic assessment of
pathergy lesions is useful in diagnosis and follow-up.
Arch Pathol Lab Med 1985;109:747–51.
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phenomenon in Behçet’s syndrome. Ann Rheum Dis
1993;52:619–20.
32 Do JE, Kwon SY, Park S, Lee E-S. Effects of vitamin D
on expression of Toll-like receptors of monocytes from
patients with Behcet’s disease. Rheumatology 2008;47:
840–8.
33 Cario E. Toll-like receptors in inflammatory bowel
diseases: a decade later. Inflamm Bowel Dis 2010;16:
1583–97.
34 Inman RD. Innate immunity of spondyloarthritis: the role
of toll-like receptors. Adv Exp Med Biol 2009;649:300–9.
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